Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2022 results with a net loss of $18.6 million, improving from $33.1 million in Q3 2021. Cash and investments totaled $142.3 million, projected to fund operations into H1 2024. Progress was noted in drug candidates targeting chronic hepatitis B (CHB), COVID-19, and NASH. The Company observed favorable safety and antiviral activity for ALG-000184 and initiated longer-term dosing cohorts. ALG-125755 is in evaluation with plans for clinical trials in CHB by Q1 2023. Upcoming presentations at The Liver Meeting (AASLD) are anticipated, showcasing positive data.
Aligos Therapeutics (Nasdaq: ALGS) announced seven poster presentations at The Liver Meeting® on November 4-8, 2022. The presentations will focus on drug candidates for chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH). Key highlights include the promising results of ALG-000184, a capsid assembly modulator showing significant declines in viral markers, and ALG-125755, a siRNA drug candidate in Phase 1 trials. Aligos aims to address unmet medical needs in liver diseases, showcasing its strategic focus on innovative antiviral therapies.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced it will release its third quarter 2022 financial results on November 2, 2022, after U.S. market close. The company focuses on developing innovative therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Founded in 2018, Aligos aims to leverage its expertise to advance its drug pipeline effectively, positioning itself as a leader in these unmet medical needs.
Aligos Therapeutics announced that its pan-Coronavirus inhibitor, ALG-097558, is set to begin clinical studies in the first half of 2023. The company presented its progress at the 20th Annual Discovery on Target Conference in Boston. The drug targets the 3CL protease, which is conserved across coronaviruses, aiming to provide effective treatment against various strains of COVID-19. CEO Lawrence Blatt emphasized the need for therapies that can withstand emerging variants, highlighting the significance of ALG-097558 in addressing unmet medical needs.
Aligos Therapeutics (Nasdaq: ALGS) initiated the dosing of ALG-125755, an siRNA targeting hepatitis B surface antigen (HBsAg), in healthy volunteers as part of Study ALG-125755-501. This study aims to evaluate safety, pharmacokinetics, and antiviral activity. Following the initial healthy volunteer study, dosing will extend to chronic hepatitis B patients in Q1 2023. CEO Lawrence Blatt highlighted the potential of siRNA drugs to lower HBsAg levels and achieve a functional cure in chronic hepatitis B. Aligos aims to develop effective antiviral therapies for viral and liver diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has filed a response and counterclaims against Janssen Biopharma in California State Superior Court. The company refutes Janssen's allegations by citing public patents and scientific literature used to develop its hepatitis B virus (HBV) portfolio. The counterclaims allege unfair competition and promissory fraud by Janssen. CEO Lawrence M. Blatt stated that Aligos will defend against these baseless claims. Aligos focuses on treating viral infections and liver diseases, leveraging its expertise to advance its drug development.
Aligos Therapeutics (Nasdaq: ALGS) reported its Q2 2022 financial results and recent progress in clinical studies. Key highlights include:
- Cash reserves of $159.3 million, sufficient to fund operations into H1 2024.
- Net loss reduced to $19.9 million, down from $29.8 million YoY.
- R&D expenses decreased to $16.5 million, primarily due to the wind-down of specific programs.
- Enrollment completed in multiple Phase 1 studies, including ALG-000184 and ALG-125755, with ongoing development of treatments for HBV and NASH.
Management remains optimistic about upcoming clinical trial applications.
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, will report its second quarter financial results on August 4, 2022, after U.S. market close. Founded in 2018, Aligos focuses on developing therapies for viral infections, particularly chronic hepatitis B and coronaviruses, as well as targeted treatments for liver diseases like nonalcoholic steatohepatitis (NASH). With a strategy built on deep expertise in drug development, Aligos aims to advance its pipeline of potentially best-in-class therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) has initiated enrollment for a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) patients in its ongoing Phase 1b study of ALG-000184. CEO Lawrence Blatt emphasized this as a crucial step towards evaluating ALG-000184's potential as a chronic suppressive therapy. Prior results indicated that the drug was well tolerated with promising antiviral activity. Data from this cohort is expected to be shared at a scientific conference in Q4 2022, aiming to assess longer-term dosing effectiveness against elevated viral levels.
Aligos Therapeutics (Nasdaq: ALGS) presented preliminary Phase 1 data from its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) programs at the 2022 European Association for the Study of the Liver Congress. Highlights include significant reductions in HBV DNA and RNA in CHB patients after 28 days of treatment with ALG-000184. Additionally, preliminary results for ALG-055009 in hyperlipidemia patients showed favorable pharmacokinetics and safety. Aligos aims for broader clinical trials and further data releases in Q3 2022.